# Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS)

> **NCT01344707** · PHASE1 · COMPLETED · sponsor: **4SC AG** · enrollment: 36 (estimated)

## Conditions studied

- Advanced Hematologic Malignancies

## Interventions

- **DRUG:** 4SC-202

## Key facts

- **NCT ID:** NCT01344707
- **Lead sponsor:** 4SC AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2015-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01344707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01344707, "Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01344707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*